Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Hypertension 3Diabetes Mellitus, Type 2 3Cushing Syndrome 3ACTH Syndrome, Ectopic 3Prostatic Neoplasms 2Pituitary ACTH Hypersecretion 2Ovarian Neoplasms 2Fallopian Tube Neoplasms 2Peritoneal Neoplasms 1Ovarian Diseases 1Neoplasms by Site 1Neoplasms 1Genital Neoplasms, Female 1Fallopian Tube Diseases 1Endometrial Neoplasms 1Carcinoma, Pancreatic Ductal 1Adrenocortical Carcinoma 1Adrenal Cortex Neoplasms 1Adenocarcinoma 1

Interventions

Paclitaxel 40Carboplatin 34Bevacizumab 29liposomal doxorubicin 20Specimen Handling 18Taxes 17olaparib 16Magnetic Resonance Spectroscopy 16pembrolizumab 15Gemcitabine 15Topotecan 13Immunoglobulin G 11Disulfides 11Biopsy 11mirvetuximab soravtansine 8niraparib 7Nivolumab 7Doxorubicin 7Cyclophosphamide 6Cisplatin 6Drug Therapy 5130-nm albumin-bound paclitaxel 5cemiplimab 4cediranib 4Letrozole 4Injections 4Docetaxel 41-dodecylpyridoxal 4sarilumab 3rucaparib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Fallopian Tube Neoplasms × relacorilant × 1 year × Clear all
NCT06906341 2026-04-14

Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers

Corcept Therapeutics

Phase 2 Recruiting
270 enrolled
Gynecologic

Fallopian Tube Diseases, Fallopian Tube Neoplasms, Genital Neoplasms, Female, Neoplasms, Neoplasms by Site, Ovarian Diseases, Ovarian Neoplasms, Peritoneal Neoplasms, Endometrial Neoplasms

NCT03776812 2025-10-07

Study of Relacorilant in Combination With Nab-Paclitaxel for Patients With Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Corcept Therapeutics

Phase 2 Completed
178 enrolled 21 charts
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡